Cargando…

Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey

BACKGROUND/AIM: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. MATERIALS AND METHODS: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. RESULTS: The median age at ruxolitinib initiation was 62 (28–87) a...

Descripción completa

Detalles Bibliográficos
Autores principales: SOYER, Nur, ALİ, Rıdvan, TURGUT, Mehmet, C. HAZNEDAROĞLU, İbrahim, YILMAZ, Fergün, AYDOĞDU, İsmet, PİR, Ali, KARAKUŞ, Volkan, ÖZGÜR, Gökhan, KİS, Cem, CERAN, Funda, İLHAN, Gül, ÖZKAN, Melda, ASLANER, Müzeyyen, İNCE, İdris, YAVAŞOĞLU, İrfan, GEDİZ, Füsun, SÖNMEZ, Mehmet, GÜVENÇ, Birol, ÖZET, Gülsüm, KAYA, Emin, VURAL, Filiz, ŞAHİN, Fahri, TÖBÜ, Mahmut, DURUSOY, Raika, SAYDAM, Güray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283435/
https://www.ncbi.nlm.nih.gov/pubmed/33315343
http://dx.doi.org/10.3906/sag-1812-70
Descripción
Sumario:BACKGROUND/AIM: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. MATERIALS AND METHODS: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. RESULTS: The median age at ruxolitinib initiation was 62 (28–87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10–40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1–55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). CONCLUSION: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.